Both BCL6 peptide inhibitors and small molecule inhibitors have been shown to have potent efficacy against B-cell lymphoma cells [83,84] and BCL6-dependent DLBCL cell lines [85]. Here, BCL6 is linked to diffuse large B-cell lymphoma.